Please login to the form below

Not currently logged in
Email:
Password:

Sanofi Genzyme

This page shows the latest Sanofi Genzyme news and features for those working in and with pharma, biotech and healthcare.

Dupixent helps put Sanofi back on growth track

Dupixent helps put Sanofi back on growth track

Gains for vaccine division Sanofi Pasteur and the company’s specialty medicines division, which along with Dupixent includes Genzyme’s rare disease drugs and multiple sclerosis therapies like Aubagio (teriflunomide), contributed ... Buoyed by an 8%

Latest news

  • Sanofi gets EU OK for Ablynx flagship drug Cablivi Sanofi gets EU OK for Ablynx flagship drug Cablivi

    EMA clears the drug to treat adults with aTTP. Sanofi has EMA approval for its acquired thrombotic thrombocytopenic purpura (aTTP) therapy Cablivi, the main asset behind its 9.3bn acquisition of ... Sanofi reckons there are around 7, 500 patients with

  • Sanofi’s rare blood disorder drug Cablivi set for European approval Sanofi’s rare blood disorder drug Cablivi set for European approval

    Rare disease drug among notable CHMP recommendations. Sanofi is closing in on EU approval of Cablivi for acquired thrombotic thrombocytopenic purpura (aTTP) – the lead asset behind its 9.3bn acquisition of ... Europe looks set to be the first market

  • Communiqué 2018 - all the winners Communiqué 2018 - all the winners

    Excellence in Communications via Meetings. OptiMiSe: an Innovative Meetings-based Learning Journey for Clinical Behaviour Change Among Multiple Sclerosis Specialist Nurses by Lucid for Sanofi Genzyme. ... Excellence in Corporate Communications –

  • Lucid’s “spellbinding” performance prompts multiple wins at Communiqué 2018 Lucid’s “spellbinding” performance prompts multiple wins at Communiqué 2018

    Meanwhile, Lucid’s work in multiple sclerosis (MS) for Sanofi Genzyme triggered another win for the group in the Excellence in Communications via Meetings category.

  • The year of the blockbuster The year of the blockbuster

    Patisiran from Alnylam and Sanofi: Patisiran is an intravenously administered RNAi therapeutic targeting the transthyretin gene for the treatment of patients with debilitating hereditary transthyretin-mediated amyloidosis. ... Together with the Genzyme

More from news
Approximately 15 fully matching, plus 64 partially matching documents found.

Latest Intelligence

  • Trust me, I’m from pharma Trust me, I’m from pharma

    Rather than assuming anything, Sanofi Genzyme took a step back and asked patients: how can we help? ... In Sanofi Genzyme’s case, it culminated in a set of briefs that were owned by the patients living with the disease.

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Voyager Therapeutics/ Sanofi (Genzyme). Gene therapy - Parkinson's disease, Friedreich's ataxia and Huntington's disease.

  • Pharma deals during January 2014 Pharma deals during January 2014

    The other deal announced by Alnylam was the expansion of its deal with Sanofi (Genzyme unit_ to develop RNAi therapeutics in rare diseases. ... In 2008 Genzyme gained rights to ataluren from PTC Therapeutics at a cost of $100m.

  • Interview: Laure Thibaud, Sanofi Interview: Laure Thibaud, Sanofi

    overnight.” . The Genzyme deal, for which Thibaud was involved in the pre-acquisition stage of the agreement, as well as the company's subsequent integration into Sanofi, was particularly exciting, she ... Chris Viehbacher has said too that he was

  • Who tops the pharma list? Who tops the pharma list?

    The latter, an antiplatelet agent it co-marketed with Sanofi, enjoyed 2011 sales of $9.4bn - but, with Plavix accounting for more than a third of BMS revenues in 2010, the ... For example, Sanofi's 2011 acquisition of Genzyme gave it access to an

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics